The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes

被引：12

作者：

Lorand-Metze, I. ^{[1
]}

Califani, S. M. V. ^{[1
]}

Ribeiro, E. ^{[1
]}

Lima, C. S. P. ^{[1
]}

Metze, K. ^{[1
]}

机构：

[1] Univ Estadual Campinas, Fac Med, BR-13081970 Campinas, SP, Brazil

来源：

LEUKEMIA RESEARCH | 2008年 / 32卷 / 02期

基金：

巴西圣保罗研究基金会;

关键词：

myelodysplastic syndromes; cell maturation; phenotypic aberrations; flow cytometry; prognosis;

D O I：

10.1016/j.leukres.2007.06.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Several phenotypic abnormalities of bone marrow (BM) hemopoietic precursors have been associated with disease progression in myelodysplastic syndromes (MDS). We analyzed the influence on overall survival of the expression of lineage and maturation-associated antigens of BM hemopoietic cells quantified in a previous study. In the univariate Cox regression the peripheral platelet count was a significant favourable factor for overall survival. Unfavorable prognostic factors were: WPSS, increase in BM CD34+ cells, increased mean fluorescence intensity (MFI) of CD13 on myelocytes, metamyelocytes and mature neutrophils as well as increased CD45 of myelocytes and mature neutrophils. In a model containing platelet count, WPSS and MFI of CD45 and CD13 on mature neutrophils, only hyperexpression of CD13 and degree of thrombocytopenia were independent risk factors. Therefore, phenotypic features that can also be obtained from PB might be useful for predicting Survival in MDS. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：211 / 213

页数：3

共 50 条

[21] Prognostic factors and scoring systems in myelodysplastic syndromes [J].

Sanz, GF ;

Sanz, MA ;

Greenberg, PL .

HAEMATOLOGICA, 1998, 83 (04) :358-368

[22] PROGNOSTIC FACTORS IN THE MYELODYSPLASTIC SYNDROMES [J].

TRICOT, GJ .

LEUKEMIA RESEARCH, 1992, 16 (01) :109-115

[23] Prognostic models in myelodysplastic syndromes [J].

Bejar, Rafael .

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2013, :504-510

[24] Chromosome and molecular abnormalities in myelodysplastic syndromes [J].

Fenaux, P .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2001, 73 (04) :429-437

[25] Chromosome and Molecular Abnormalities in Myelodysplastic Syndromes [J].

Pierre Fenaux .

International Journal of Hematology, 2001, 73 :429-437

[26] Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes.: Its value in patients without karyotypic abnormalities [J].

Arroyo, JL ;

Fernández, ME ;

Hernández, JIM ;

Orfao, A ;

San Miguel, JF ;

del Cañizo, MC .

HEMATOLOGY JOURNAL, 2004, 5 (03) :227-233

[27] Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes [J].

Chu, Sung-Chao ;

Wang, Tso-Fu ;

Li, Chi-Cheng ;

Kao, Ruey-Ho ;

Li, Dian-Kun ;

Su, Yu-Chieh ;

Wells, Denise A. ;

Loken, Michael R. .

LEUKEMIA RESEARCH, 2011, 35 (07) :868-873

[28] Association between lymphocyte-associated ratios, C-reactive protein and prognostic value in myelodysplastic syndromes [J].

Cai, Hong-kai ;

Jiang, Lin ;

Gong, Jian-bin ;

Luo, Wen-da ;

Zhu, Xia-Yin .

HEMATOLOGY, 2025, 30 (01)

[29] Altered neutrophil maturation patterns that limit identification of myelodysplastic syndromes [J].

Monaghan, Sara A. ;

Surti, Urvashi ;

Doty, Ketah ;

Craig, Fiona E. .

CYTOMETRY PART B-CLINICAL CYTOMETRY, 2012, 82B (04) :217-228

[30] Autoimmune disorders associated with myelodysplastic syndromes: clinical, prognostic and therapeutic implications [J].

Fozza, Claudio ;

Murtas, Andrea ;

Caocci, Giovanni ;

La Nasa, Giorgio .

LEUKEMIA RESEARCH, 2022, 117

← 1 2 3 4 5 →